{
  "ticker": "RARE",
  "company_name": "Ultragenyx Pharmaceutical",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT07159581",
      "title": "Gene Therapy for Wilson Disease Evaluated by 64Cu PET/CT",
      "status": "ENROLLING_BY_INVITATION",
      "phase": "",
      "condition": "Wilson Disease",
      "start_date": "2025-07-08",
      "completion_date": "2026-01",
      "enrollment": 0,
      "sponsor": "Thomas Damgaard Sandahl"
    },
    {
      "nct_id": "NCT05933200",
      "title": "A Study to Determine the Effect of Triheptanoin Compared With Even-Chain MCT on MCEs in Pediatric Patients With LC-FAOD",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
      "start_date": "2023-02-28",
      "completion_date": "2027-08",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT03665636",
      "title": "Anaplerotic Therapy Using Triheptanoin for Patients With Glycogen Storage Disease Type I",
      "status": "COMPLETED",
      "phase": "EARLY_PHASE1",
      "condition": "Glycogen Storage Disease Type I",
      "start_date": "2020-10-16",
      "completion_date": "2021-10-21",
      "enrollment": 0,
      "sponsor": "Areeg El-Gharbawy"
    },
    {
      "nct_id": "NCT02991144",
      "title": "Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset Ornithine Transcarbamylase (OTC) Deficiency",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Ornithine Transcarbamylase (OTC) Deficiency",
      "start_date": "2017-07-31",
      "completion_date": "2021-12-16",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT04909346",
      "title": "Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease",
      "status": "TERMINATED",
      "phase": "",
      "condition": "Ornithine Transcarbamylase Deficiency, Wilson Disease, Glycogen Storage Disease Type IA",
      "start_date": "2021-06-23",
      "completion_date": "2022-11-17",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT00947960",
      "title": "Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Adult Polyglucosan Body Disease, Glycogen Brancher Enzyme Deficiency, Glycogen Storage Disease Type IV",
      "start_date": "2009-06",
      "completion_date": "2015-07",
      "enrollment": 0,
      "sponsor": "Baylor Research Institute"
    },
    {
      "nct_id": "NCT05768854",
      "title": "Setrusumab vs Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta",
      "status": "ACTIVE_NOT_RECRUITING",
      "phase": "PHASE3",
      "condition": "Osteogenesis Imperfecta",
      "start_date": "2023-06-14",
      "completion_date": "2027-04",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT04311307",
      "title": "Endogenous Glucose Production in Patients With Glycogen Storage Disease Type Ia",
      "status": "COMPLETED",
      "phase": "PHASE1, PHASE2",
      "condition": "Glycogen Storage Disease Type IA",
      "start_date": "2021-01-19",
      "completion_date": "2022-02-07",
      "enrollment": 0,
      "sponsor": "University Medical Center Groningen"
    },
    {
      "nct_id": "NCT02599961",
      "title": "Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)",
      "status": "TERMINATED",
      "phase": "PHASE2",
      "condition": "Glucose Transporter Type 1 Deficiency Syndrome",
      "start_date": "2015-09-10",
      "completion_date": "2019-10-22",
      "enrollment": 0,
      "sponsor": "Ultragenyx Pharmaceutical Inc"
    },
    {
      "nct_id": "NCT02036853",
      "title": "An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)",
      "start_date": "2014-02-20",
      "completion_date": "2019-06-30",
      "enrollment": 0,
      "sponsor": "Adrian Lacy"
    }
  ],
  "summary": {
    "total_trials": 50,
    "by_phase": {
      "": 14,
      "PHASE3": 9,
      "EARLY_PHASE1": 1,
      "PHASE1, PHASE2": 5,
      "PHASE2": 18,
      "PHASE1": 2,
      "PHASE2, PHASE3": 1
    },
    "by_status": {
      "ENROLLING_BY_INVITATION": 1,
      "ACTIVE_NOT_RECRUITING": 8,
      "COMPLETED": 23,
      "TERMINATED": 8,
      "UNKNOWN": 2,
      "RECRUITING": 2,
      "NO_LONGER_AVAILABLE": 2,
      "WITHDRAWN": 2,
      "SUSPENDED": 1,
      "AVAILABLE": 1
    },
    "active_trials": 11,
    "completed_trials": 23,
    "conditions": [
      "Adult Polyglucosan Body Disease, Glycogen Brancher Enzyme Deficiency, Glycogen Storage Disease Type IV",
      "Angelman Syndrome",
      "Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency, Carnitine-acylcarnitine Translocase (CACT) Deficiency",
      "Chronic-kidney Disease Stage 5D on Stable Hemodialysis",
      "GNE Myopathy, Hereditary Inclusion Body Myopathy (HIBM)",
      "Glucose Transporter Type 1 Deficiency Syndrome",
      "Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)",
      "Glucose Transporter Type-1 Deficiency Syndrome (Glut1 DS)",
      "Glycogen Storage Disease Type I",
      "Glycogen Storage Disease Type IA",
      "Glycogen Storage Disease Type IA, Von Gierke's Disease (GSD Type Ia)",
      "Glycogen Storage Disease Type III",
      "Glycogen Storage Disease Type V",
      "Hereditary Inclusion Body Myopathy (HIBM)",
      "Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy",
      "Hereditary Inclusion Body Myopathy, Distal Myopathy With Rimmed Vacuoles, Distal Myopathy, Nonaka Type, GNE Myopathy, Quadriceps Sparing Myopathy, Inclusion Body Myopathy 2",
      "Hereditary Inclusion Body Myopathy, GNE Myopathy, Nonaka Disease, Quadriceps Sparing Myopathy (QSM), Distal Myopathy With Rimmed Vacuoles (DMRV)",
      "Hypophosphatasia",
      "Hypophosphatemia, Hypophosphatemic Rickets, Pain, Chronic",
      "Long Chain Fatty Acid Oxidation Disorders",
      "Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)",
      "Medium-chain Acyl-CoA Dehydrogenase Deficiency",
      "Mucopolysaccharidosis Type 7",
      "Ornithine Transcarbamylase (OTC) Deficiency",
      "Ornithine Transcarbamylase Deficiency",
      "Ornithine Transcarbamylase Deficiency, Wilson Disease, Glycogen Storage Disease Type IA",
      "Osteogenesis Imperfecta",
      "Osteopenia, Osteoporosis",
      "Pyruvate Dehydrogenase Complex Deficiency",
      "Rett Syndrome",
      "Sly Syndrome, MPS VII, Mucopolysaccharidosis, Mucopolysaccharidosis VII",
      "Tarui Disease, Debrancher Deficiency, GYG1 DEFICIENCY",
      "Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2), Mitochondrial Trifunctional Protein Deficiency, Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency, Glycogen Storage Disorders, Pyruvate Carboxylase Deficiency Disease, ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of, Barth Syndrome",
      "Wilson Disease",
      "X-linked Hypophosphatemia, Hypophosphatemic Rickets"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-05T17:58:36.674908",
    "search_query": "Ultragenyx Pharmaceutical",
    "url": "https://clinicaltrials.gov/search?term=Ultragenyx+Pharmaceutical"
  }
}